HB1725 aims to increase access to biosimilar medicines in Washington by reducing barriers and promoting their use.

HB1725 seeks to enhance access to biosimilar medicines in Washington by eliminating barriers and encouraging their use. The bill mandates that health carriers and prescription drug utilization management entities provide a clear process for patients and providers to request exceptions for prescription drug coverage. It also requires health carriers to cover emergency supplies of drugs when necessary and to disclose all rules and criteria related to prescription drug utilization management.

HB1725 aims to increase access to biosimilar medicines in Washington by reducing barriers and promoting their use.

HB1725 seeks to enhance access to biosimilar medicines in Washington by eliminating barriers and encouraging their use. The bill mandates that health carriers and prescription drug utilization management entities provide a clear process for patients and providers to request exceptions for prescription drug coverage. It also requires health carriers to cover emergency supplies of drugs when necessary and to disclose all rules and criteria related to prescription drug utilization management.